A Multi-Center, Open Label, Phase I, Dose Finding and Expansion Study of RO7051790 Administered Orally in Patients With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2017
At a glance
- Drugs RG 6016 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 20 Jul 2017 According to an Oryzon media release, Roche is planning to finalize this trial in the following months.
- 08 Jun 2017 Planned End Date changed from 1 Aug 2019 to 23 Sep 2019.
- 08 Jun 2017 Planned primary completion date changed from 1 Aug 2019 to 23 Sep 2019.